Moderna (MRNA) Stock Looks Too Expensive For Its Sales Story

Moderna has seen its share price move sharply over the past year, helped by fresh headlines and shifting expectations for its pipeline. That kind of run naturally raises the question of whether today's US$190.01 price tag still lines up with the sales the business is generating and investors expect it to produce.

• Over the past 12 months, Moderna has delivered a very large share price gain of about 7x, which puts a lot of weight on whether its current market value can be supported by the revenue story behind it.
• Recent news has pulled expectations in different directions, from upbeat reactions to new investment talks and oncology trial progress to a broker downgrade that flagged sales forecasts as potentially too optimistic. Investors are effectively being asked how much future top line they are comfortable baking into today's valuation.
• The analysts covering Moderna have run their own numbers. See what analysts think Moderna's shares could be worth.

The issue now is whether Moderna's current share price can be squared with its sales once you strip away the recent headlines and focus on what the market is actually paying for each dollar of revenue.

If you are weighing whether Moderna's 1 year surge is justified by its sales, it can help to compare that story with 31 high quality undervalued stocks.

Has Moderna Run Too Far on Sales?

P/S is usually a useful way to look at Moderna because revenue arrives well before consistent earnings for many biotech businesses. On this measure, the stock trades at about 34.0x sales, which is far above the broader Biotechs group at roughly 12.4x and also ahead of the peer set around 6.6x. That is a lot of future revenue being reflected in the share price for each current dollar of turnover.

On a more tailored yardstick that adjusts for Moderna's margins, scale and risk profile, the model points to a much lower P/S as a fair anchor. The wide gap suggests this framework sees the shares as overvalued on sales and that losses and execution risk are pulling the implied fair level down. As a result, the output is better read as a warning signal rather than a precise target. Despite the recent rally on UAE talks and oncology trial anticipation, the current P/S still prices Moderna as a very expensive revenue story on this screen. Explore the numbers behind Moderna's P/S valuation.

The Moderna Narrative: What Would Justify Today's Price?

Narratives on Moderna’s Community page pick up where this valuation puzzle leaves off by spelling out what would need to happen to future growth, profitability and earnings power for the stock to look meaningfully richer or cheaper than today’s price. Each one links its number to a clear view on how Moderna’s revenue trajectory, margin profile and risk picture could evolve, which gives you something concrete to revisit as new information lands.

One of the top community narratives on Moderna: 59% overvalued

"Bearish analysts, including those that moved to Sell, argue that Moderna's share price reaction already prices in very broad usage of intismeran…"

Discover why this Narrative puts Moderna at 59% overvalued.

One more piece of the Moderna puzzle worth checking

Before moving on from Moderna, it is worth asking who is steering the ship and how their pay packets line up with the risks and rewards that shareholders are carrying. See who runs Moderna and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com